Relative Strength Index (RSI)
|Bid||14.21 x 3000|
|Ask||14.23 x 800|
|Day's Range||13.88 - 16.03|
|52 Week Range||5.51 - 18.58|
|Beta (5Y Monthly)||0.77|
|PE Ratio (TTM)||28.52|
|Earnings Date||May 08, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Feb 01, 2019|
|1y Target Est||9.00|
CINCINNATI, May 26, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that.
Meridian Bioscience, Inc.’s (VIVO) Board of Directors announced that Tony Serafini-Lamanna has been promoted to Executive Vice President of Diagnostics. Jack Kenny remains Chief Executive Officer of Meridian, while passing responsibility of the Diagnostics division to Mr. Serafini-Lamanna, who becomes an officer of the company.
With me are Jack Kenny, Chief Executive Officer; and Bryan Baldasare, Chief Financial Officer. With regards to our calendar, Jack and Bryan will be participating in a virtual fireside chat as part of the William Blair Annual Growth Stock Conference on Tuesday, June 9, 2020.
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 187.50% and 0.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Meridian Bioscience (NASDAQ:VIVO) rose 8.4% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were up 21.05% year over year to $0.23, which beat the estimate of $0.08.Revenue of $57,296,000 rose by 14.03% from the same period last year, which beat the estimate of $49,260,000.Guidance Meridian Bioscience hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 08, 2020View more earnings on VIVOTime: 11:03 PM ETWebcast URL: https://investor.meridianbioscience.com/events/event-details/q2-2020-financial-results-conference-callPrice Action Company's 52-week high was at $16.4252-week low: $5.51Price action over last quarter: Up 126.72%Company Overview Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment contributes the majority of revenue & manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.See more from Benzinga * Stocks That Hit 52-Week Highs On Thursday * Stocks That Hit 52-Week Highs On Wednesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
CINCINNATI, May 08, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2020. Second Quarter Fiscal.
Meridian Bioscience, Inc. (VIVO), a leading provider of diagnostic testing solutions and life science raw materials, is pleased to announce its collaboration with QuantuMDx on its newly launched SARS-CoV-2 assay for laboratory use. Since the beginning of the coronavirus outbreak, Meridian has enabled the manufacture of millions of COVID-19 assays through its partnerships with over 35 diagnostic companies around the globe. In the last few months, Meridian has multiplied its production capabilities to meet the demand of its customers including QuantuMDx.
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, has completed its previously announced acquisition of Exalenz Bioscience Ltd., the Modiin, Israel based provider of the BreathID® Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori. According to the CDC, approximately two thirds of the global population is infected with H. pylori, a leading cause of peptic ulcers and gastric cancer.
Meridian Bioscience, Inc. (VIVO) announced today the launch of a novel enzyme master mix (Inhibitor Tolerant 1-step RT-qPCR Mix) that eliminates the need to use an RNA extraction kit prior to running the patient sample through a molecular assay. To date, most COVID-19 molecular assays require laboratories to first isolate and purify the SARS-CoV-2 viral RNA from a patient sample (saliva or nasopharyngeal). To address these shortfalls, scientists at Meridian have successfully developed a proprietary master mix formulation, which when combined with SARS-CoV-2 primers and probes, will enable laboratories to eliminate the SARS-CoV-2 viral RNA purification step.
CINCINNATI, April 16, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter.
Jack Kenny has been the CEO of Meridian Bioscience, Inc. (NASDAQ:VIVO) since 2017. First, this article will compare...
CINCINNATI, April 14, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), announced today the launch of several novel recombinant antigens critical for the development of.
The Life Science segment achieved record sales in the quarter, produced by unprecedented demand for products specifically designed for the detection of RNA viruses such as SARS-CoV-2.
Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary revenue results for its second quarter of fiscal 2020. The Company expects second quarter of fiscal 2020 revenues to be approximately $57 million, compared to $50.2 million in the second quarter of fiscal 2019.
In order to help expedite such development, Meridian is pleased to provide from stock its specialized enzyme formulations to manufacturers of a COVID-19 molecular detection assay at no cost for the purpose of initial testing and evaluation. Following the successful development of a COVID-19 detection assay or kit, it is Meridian’s commitment to continue to manufacture and supply its propriety formulations at commercial scale in order to meet the global demand.
CINCINNATI, March 16, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of immunoassay, molecular, and blood chemistry diagnostic testing solutions, today announced.
Investors who take an interest in Meridian Bioscience, Inc. (NASDAQ:VIVO) should definitely note that the President...
To the annoyance of some shareholders, Meridian Bioscience (NASDAQ:VIVO) shares are down a considerable 33% in the...
The U.S. stock market rallied on Wednesday, with the Dow Jones industrial average shooting up nearly 1,200 points following a Super Tuesday surge for Democratic presidential candidate Joe Biden. Shares in Cincinnati-based companies rode that wave.
CINCINNATI, Feb. 26, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), following the extremely successful launch of the Lyo-Ready qPCR mixes, is proud to introduce today its.
Greater Cincinnati stocks took a beating on Monday as the stock market plummeted in the wake of an escalation in coronavirus cases.